Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (43)

1

Optimising surgical anastomosis in ileocolic resection for Crohn's disease with respect to recurrence and functionality : two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES)

enthalten in: BMC surgery | 2024

von Haanappel, A. | Bellato, V. | Buskens, C. | +14

2

Neutrophil-only Histological Assessment of Ulcerative Colitis Correlates with Endoscopic Activity and Predicts Long-term Outcomes in a Multicentre Study

enthalten in: Journal of Crohn's & colitis | 2023

von Parigi, T. | Cannatelli, R. | Nardone, O. | +14

3

Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor : A multicentre IG-IBD study

enthalten in: United European gastroenterology journal | 2023

von Dragoni, G. | Castiglione, F. | Bezzio, C. | +18

CommentIn: United European Gastroenterol J. 2023 Apr;11(3):267-268. - PMID 36922635

4

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases : A Real-Life, Multicenter, Observational Study

enthalten in: Inflammatory bowel diseases | 2023

von Tursi, A. | Mocci, G. | Allegretta, L. | +47

ErratumIn: Inflamm Bowel Dis. 2022 Oct 3;28(10):e145. - PMID 35820045

5

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2023

von Peyrin-Biroulet, L. | Rahier, J. | Kirchgesner, J. | +120

6

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease : A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2022

von Tursi, A. | Mocci, G. | Cuomo, A. | +89

7

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab : A Real-World Multicentre European Study

enthalten in: Journal of Crohn's & colitis | 2022

von Yanai, H. | Kagramanova, A. | Knyazev, O. | +68

8

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

enthalten in: The American journal of gastroenterology | 2022

von Onali, S. | Pugliese, D. | Caprioli, F. | +28

9

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease : a multicentre, randomised, double-blind, parallel-group, phase 3b trial

enthalten in: Lancet (London, England) | 2022

von Sands, B. | Irving, P. | Hoops, T. | +117

CommentIn: Lancet. 2022 Jun 11;399(10342):2169-2171. - PMID 35691307

10

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies : Randomized SERENE CD Trial Results

enthalten in: Gastroenterology | 2022

von D'Haens, G. | Sandborn, W. | Loftus, E. | +19

CommentIn: Gastroenterology. 2022 Jun;162(7):1831-1832. - PMID 35364063

1
2
3
4
5
Nächster »
[5]